Drug intelligence / Profile preview

AJP001

Development stage: Preclinical
Lead developer: FunPep
Modality: Peptides
Administration: Subcutaneous, Intramuscular

Overview

AJP001 is a proprietary carrier peptide and adjuvant developed by FunPep, serving as a core component of the company's STEP UP (Search Technology for Functional Peptides) platform. It is designed to be conjugated with target peptide antigens to overcome the typically low immunogenicity of short peptides. AJP001 functions by facilitating the delivery of the antigen and providing adjuvant activity that stimulates the production of high-titer antibodies against the target protein. Rather than being a standalone therapeutic, AJP001 is a platform technology component integrated into various peptide vaccines in FunPep's pipeline, such as FPP003 (targeting IL-17A) and FPP004 (targeting IgE).

Other names: STEP UP carrier peptideFunPep adjuvant peptide

Beyond the preview

Go deeper on AJP001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AJP001.

Explore the full profile